Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its ...
Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...
Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...
The average one-year price target for Vor Biopharma (NasdaqGS:VOR) has been revised to $37.13 / share. This is a decrease of ...
In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...
Vor Biopharma Inc. (NASDAQ:VOR) shares are trading higher on Friday after the company announced it has entered into a securities purchase agreement for a private investment in public equity financing ...
VOR pivoted from cell therapy to in-licensing telitacicept, securing $175M in private placement but at the cost of massive dilution. Telitacicept offers multi-billion market potential if global trials ...
BOSTON--(BUSINESS WIRE)--Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, today announced a $42 ...
New data from Vor Bio show that its hematopoietic stem cells have, so far, successfully engrafted in the first seven patients with relapsed or refractory acute myeloid leukemia and that the new cells ...
Vor Bio announces a $55.6 million PIPE to fund clinical trials and expects to report updated data in 2025. Vor Bio, a clinical-stage cell and genome engineering company, announced a securities ...
Three years after Pulitzer Prize-winning writer and oncologist Dr. Siddhartha Mukherjee founded Vor Biopharma, the company finally has its first executive. Robert Ang, formerly the chief business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results